China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

On September 22, 2022 Keymed Biosciences (HKEX:02162) reported that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted CMG901 the Breakthrough Therapy Designation for the treatment of advanced gastric and gastroesophageal junction(GEJ) cancer which have relapsed and/or are intolerant to prior therapies (Press release, Keymed Biosciences, SEP 22, 2022, View Source;gastroesophageal-junction-cancer-301630843.html [SID1234621373]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About CMG901

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors. In April 2022, the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation[i] and Orphan Drug Designation[ii] as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancer which are resistant/refractory to prior therapies.

About CDE’s Breakthrough Therapy Designation

CDE’s Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages. A breakthrough therapy must provide effective treatment for a seriously debilitating or life-threatening condition that has no effective therapy or demonstrate substantial improvement over available therapies. According to the CDE, BTD provides opportunities for more intensive CDE guidance and discussion with respect to clinical trials and development strategy, and for priority review later.